Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from Cipla Ltd ( (IN:CIPLA) ) is now available.
Cipla Ltd has announced that it received final approval from the United States Food and Drug Administration for its New Drug Application for Nilotinib Capsules, which are used to treat Philadelphia chromosome-positive chronic myeloid leukemia. This approval allows Cipla to launch the product in the U.S. market in the fiscal year 2025-26, potentially strengthening its presence in the oncology segment and expanding its product offerings to stakeholders in the U.S.
More about Cipla Ltd
Cipla Ltd is a prominent pharmaceutical company headquartered in Mumbai, India. It specializes in producing a wide range of pharmaceutical products, focusing on treatments for respiratory, cardiovascular diseases, and other chronic ailments. The company has a significant market presence in both domestic and international markets.
YTD Price Performance: -4.36%
Average Trading Volume: 60,184
Current Market Cap: 1197B INR
For an in-depth examination of CIPLA stock, go to TipRanks’ Stock Analysis page.
